DOCSLIB.ORG

Antivirals Publications, 2010–2011

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antivirals Publications, 2010–2011 APPENDIX 12 Antivirals publications, 2010–2011 1. 2009. [Black triangle down] Tamiflu – the wrong message? Drug Ther.Bull. 47:97. doi:47/9/97 [pii];10.1136/dtb.2009.08.0034 [doi]. 2. 2009. A caution about giving Tamiflu to children. Child Health Alert. 27:4–5. 3. 2009. Antiviral drugs for influenza. Med.Lett.Drugs Ther. 51:89–92. 4. 2009. Campus response to novel influenza H1N1. J.Am.Coll.Health 58:281–289. doi:U6265414166J437M [pii];10.1080/07448480903482510 [doi]. 5. 2009. Case management for influenza. J.Indian Med.Assoc. 107:528–530. 6. 2009. Epidemiology of seasonal, avian and pandemic influenza. J.Indian Med.Assoc. 107:506–507. 7. 2009. Foreword: this issue of the Seton Hall Law Review presents contributions to Preparing for Pharmaceutical Response to Pandemic Influenza, a two-day Symposium held at Seton hall University School of Law in the fall of 2008. Seton.Hall.Law Rev. 39:1103–1109. 8. 2009. Pandemic preparedness. Alta.RN. 65:20–27. 9. 2009. Update on oseltamivir-resistant pandemic A (H1N1) 10. 2009 influenza virus: January 2010. Wkly.Epidemiol.Rec. 85:37–40. 11. 2010. [Technical report on the 2009 influenza A (H1N1) pandemic]. An.Pediatr.(Barc.) 72:81–35. doi:S1695-4033(09)00614-6 [pii];10.1016/j.anpedi.2009.11.002 [doi]. 12. 2010. [Treatment with antiviral agents]. An.Pediatr.(Barc.) 72:81–85. doi:S1695-4033(09)00621-3 [pii];10.1016/j.anpedi.2009.11.009 [doi]. 13. 2010. 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care – New York City, 2009. MMWR Morb.Mortal.Wkly.Rep. 59:321–326. doi:mm5911a1 [pii]. 14. 2010. A pandemic of hindsight? Nature 465:985. doi:465985a [pii];10.1038/465985a [doi]. 15. 2010. Fatal H1N1 infection in an HIV positive woman. Negative flu tests, HIV infection delay treatment. AIDS Alert. 25:9–10. 16. 2010. Influenza activity – United States and worldwide, June 13–September 25, 2010. MMWR Morb. Mortal.Wkly.Rep. 59:1270–1273. doi:mm5939a3 [pii]. 17. 2010. Outbreak of 2009 pandemic influenza A (H1N1) on a Peruvian Navy ship – June–July 2009. MMWR Morb.Mortal.Wkly.Rep. 59:162–165. doi:mm5906a3 [pii]. 18. 2010. Outbreaks of 2009 pandemic influenza A (H1N1) among long-term-care facility residents – three states, 2009. MMWR Morb.Mortal.Wkly.Rep. 59:74–77. doi:mm5903a3 [pii]. 19. 2010. Patient education series. Seasonal influenza (the flu). Nursing. 40:33. doi:10.1097/01. NURSE.0000387238.05776.38 [doi];00152193-201009000-00011 [pii]. 20. 2010. Patient information. Influenza. Am.Fam.Physician 82:1097. doi:p722 [pii]. 211 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA 21. 2010. Patients hospitalized with 2009 pandemic influenza A (H1N1) – New York City, May 2009. MMWR Morb.Mortal.Wkly.Rep. 58:1436–1440. doi:mm5851a2 [pii]. 22. 2010. Update: influenza activity – United States, 2009–10 season. MMWR Morb.Mortal.Wkly.Rep. 59:901–908. doi:mm5929a2 [pii]. 23. 2010. Update: influenza activity – United States, October 3–December 11, 2010. MMWR Morb. Mortal.Wkly.Rep. 59:1651–1655. doi:mm5950a4 [pii]. 24. 2011. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture]. Antibiot.Khimioter. 56:3–9. 25. 2011. Antiviral drugs for influenza. Med.Lett.Drugs Ther. 53:1–3. 26. 2011. Infectious disease. Antiviral agents for the treatment and chemoprophylaxis of influenza. Ann. Emerg.Med. 58:299–303. doi:S0196-0644(11)01304-7 [pii];10.1016/j.annemergmed.2011.07.007 [doi]. 27. 2011. Recommended composition of influenza virus vaccines for use in the 2011–2012 northern hemisphere influenza season. Wkly.Epidemiol.Rec. 86:86–90. 28. 2011. Update: influenza activity – United States, October 3, 2010–February 5, 2011. MMWR Morb. Mortal.Wkly.Rep. 60:175–181. doi:mm6006a4 [pii]. 29. Aardema, H., J. E. Tulleken, R. J. van den Biggelaar, B. A. Wolters, C. M. de Jager, C. A. Boucher, and A. Riezebos-Brilman. 2010. [Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in the case of an intensive care patient]. Ned.Tijdschr.Geneeskd. 154:A1634. 30. Abdel-Rahman, S. M., J. G. Newland, and G. L. Kearns. 2011. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr.Drugs 13:19–31. doi:3 [pii];10.2165/11536950-000000000-00000 [doi]. 31. Abdo, A., C. Alfonso, G. Diaz, M. Wilford, M. Rocha, and N. Verdecia. 2011. Fatal 2009 pandemic influenza A (H1N1) in a bone marrow transplant recipient. J.Infect.Dev.Ctries. 5:132–137. 32. Abed, Y., P. Simon, and G. Boivin. 2010. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. Antimicrob.Agents Chemother. 54:2819–2822. doi:AAC.01681-09 [pii];10.1128/ AAC.01681-09 [doi]. 33. Accinelli, C., M. L. Sacca, J. Fick, M. Mencarelli, R. Lindberg, and B. Olsen. 2010. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments. Chemosphere 79:891–897. doi:S0045-6535(10)00168-2 [pii];10.1016/j.chemosphere.2010.02.022 [doi]. 34. Acosta, E. P. and D. W. Kimberlin. 2010. Determination of appropriate dosing of influenza drugs in pediatric patients. Clin.Pharmacol.Ther. 88:704–707. doi:clpt2010173 [pii];10.1038/clpt.2010.173 [doi]. 35. Acosta, E. P., P. Jester, P. Gal, J. Wimmer, J. Wade, R. J. Whitley, and D. W. Kimberlin. 2010. Oseltamivir dosing for influenza infection in premature neonates. J.Infect.Dis. 202:563–566. doi:10.1086/654930 [doi]. 36. Adalja, A. 2009. Optimization of antiviral prescribing for influenza. J.Hosp.Med. 4:E28. doi:10.1002/ jhm.538 [doi]. 37. Adalja, A. A. 2010. Hematemesis in a 2009 H1N1 influenza patient. Am.J.Emerg.Med. 28:846–4. doi:S0735-6757(09)00636-6 [pii];10.1016/j.ajem.2009.12.012 [doi]. 38. Adams, S. and C. Sandrock. 2010. Avian influenza: update. Med.Princ.Pract. 19:421–432. doi:000320299 [pii];10.1159/000320299 [doi]. 212 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011 39. Adisasmito, W., B. M. Hunter, R. Krumkamp, K. Latief, J. W. Rudge, P. Hanvoravongchai, and R. J. Coker. 2011. Pandemic Influenza and Health System Resource Gaps in Bali: An Analysis Through a Resource Transmission Dynamics Model. Asia Pac.J.Public Health. doi:1010539511421365 [pii];10.1177/1010539511421365 [doi]. 40. Adisasmito, W., P. K. Chan, N. Lee, A. F. Oner, V. Gasimov, F. Aghayev, M. Zaman, E. Bamgboye, N. Dogan, R. Coker, K. Starzyk, N. A. Dreyer, and S. Toovey. 2010. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J.Infect.Dis. 202:1154– 1160. doi:10.1086/656316 [doi]. 41. Adisasmito, W., P. K. Chan, N. Lee, A. F. Oner, V. Gasimov, M. Zaman, E. Bamgboye, N. Dogan, K. Starzyk, N. A. Dreyer, and S. Toovey. 2011. Strengthening observational evidence for antiviral effectiveness in influenza A (H5N1). J.Infect.Dis. 204:810–811. doi:jir398 [pii];10.1093/infdis/jir398 [doi]. 42. Aeffner, F., Z. P. Traylor, E. N. Yu, and I. C. Davis. 2011. Double-stranded RNA induces similar pulmonary dysfunction to respiratory syncytial virus in BALB/c mice. Am.J.Physiol Lung Cell Mol. Physiol 301:L99–L109. doi:ajplung.00398.2010 [pii];10.1152/ajplung.00398.2010 [doi]. 43. Agrati, C., C. Gioia, E. Lalle, E. Cimini, C. Castilletti, O. Armignacco, F. N. Lauria, F. Ferraro, M. Antonini, G. Ippolito, M. R. Capobianchi, and F. Martini. 2010. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J.Infect.Dis. 202:681–689. doi:10.1086/655469 [doi]. 44. Agrawal, A. S., M. Sarkar, S. Ghosh, T. Roy, S. Chakrabarti, R. Lal, A. C. Mishra, M. S. Chadha, and M. Chawla-Sarkar. 2010. Genetic characterization of circulating seasonal Influenza A viruses (2005– 2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India. Infect. Genet.Evol. 10:1188–1198. doi:S1567-1348(10)00207-8 [pii];10.1016/j.meegid.2010.07.019 [doi]. 45. Agrawal, R., P. V. Rewatkar, G. R. Kokil, A. Verma, and A. Kalra. 2010. Oseltamivir: a first line defense against swine flu. Med.Chem. 6:247–251. doi:BSP/MC/Epub/052 [pii]. 46. Ai, H., F. Zheng, C. Zhu, T. Sun, L. Zhang, X. Liu, X. Li, G. Zhu, and H. Liu. 2010. Discovery of novel influenza inhibitors targeting the interaction of dsRNA with the NS1 protein by structure-based virtual screening. Int.J.Bioinform.Res.Appl. 6:449–460. doi:32Q1497545044537 [pii]. 47. Ainai, A., T. Ichinohe, S. Tamura, T. Kurata, T. Sata, M. Tashiro, and H. Hasegawa. 2010. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J.Med.Virol. 82:476–484. doi:10.1002/jmv.21694 [doi]. 48. Akyuz, S., A. Yilmaz, M. Bulbul, O. Erdogan, R. Renda, and G. Demircin. 2011. Do immunosupressive patients really have a severe outcome with H1N1 virus infection? J.Trop.Pediatr. 57:129–131. doi:fmq054 [pii];10.1093/tropej/fmq054 [doi]. 49. Al Aklabi, M. M., J. G. Weinkauf, A. Humar, and N. Ghorpade. 2010. Successful bilateral lung transplantation in a patient with end-stage lung disease and positive novel influenza virus (H1N1). J.Heart Lung Transplant. 29:898–899. doi:S1053-2498(10)00274-3 [pii];10.1016/j. healun.2010.04.017 [doi]. 50. Al-Baghli, F. and W. Al-Ateeqi. 2011. Encephalitis-associated pandemic A (H1N1) 2009 in a Kuwaiti girl. Med.Princ.Pract. 20:191–195. doi:000321276 [pii];10.1159/000321276 [doi]. 51. Albohy, A., S.
Load more

Recommended publications
  • Characterizing Immunogenetic Factors Associated with Influenza Cross- Reactive Responses and Disease Severity
    Characterizing immunogenetic factors associated with Influenza cross- reactive responses and disease severity By Dr. Yoav Keynan M.D A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of DOCTOR OF PHILOSOPHY Department of Medical Microbiology University of Manitoba Winnipeg Copyright © 2013 by Yoav Keynan Acknowledgements: To my committee members: Dr. Coombs, Dr. Aoki, Dr. Soussi-gounni for your patience and invaluable advice, with diverse backgrounds, your input has been instrumental to the completion of this project. To my mentor, Dr. Fowke- for making my decision to migrate to your lab the best career decision I have made; for guiding me in this research project and for being an advocate and supporter along the course of the years. The most important lessons I have learned from you are not limited to science or grant writing, but more importantly, the optimism and positive attitude (sometimes bordering with delusion) that instills belief and motivation. To Dr. Rubinstein- for your advice and mentoring during the combined infectious diseases and PhD training. For the open doors, listening and support along the frequently bifurcating paths. To the Fowke lab team past and present- that make this lab a second home. Special thanks to Steve for your assistance over the past 8 years. To Dr. Plummer, for giving me the initial opportunity to embark on a research career in Winnipeg. To Dr. Ball for your support and collaboration. To the Ball Lab members, for the numerous fruitful discussions. To Dr. Meyers for the numerous projects and continued collaboration.
    [Show full text]
  • Integrated Computational Approach for Virtual Hit Identification Against
    International Journal of Molecular Sciences Article Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40 Muhammad Usman Mirza 1,2,*,† and Nazia Ikram 2 1 Centre for Research in Molecular Medicine (CRiMM), The University of Lahore, Defense Road, Lahore 54000, Pakistan 2 Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54000, Pakistan; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +92-333-839-6037 † Current address: Department of Pharmaceutical and Pharmacological Sciences, Rega Institute for Medical Research, Medicinal Chemistry, University of Leuven, Leuven B-3000, Belgium. Academic Editors: Christo Z. Christov and Tatyana Karabencheva-Christova Received: 28 July 2016; Accepted: 22 September 2016; Published: 26 October 2016 Abstract: The Ebola virus (EBOV) has been recognised for nearly 40 years, with the most recent EBOV outbreak being in West Africa, where it created a humanitarian crisis. Mortalities reported up to 30 March 2016 totalled 11,307. However, up until now, EBOV drugs have been far from achieving regulatory (FDA) approval. It is therefore essential to identify parent compounds that have the potential to be developed into effective drugs. Studies on Ebola viral proteins have shown that some can elicit an immunological response in mice, and these are now considered essential components of a vaccine designed to protect against Ebola haemorrhagic fever. The current study focuses on chemoinformatic approaches to identify virtual hits against Ebola viral proteins (VP35 and VP40), including protein binding site prediction, drug-likeness, pharmacokinetic and pharmacodynamic properties, metabolic site prediction, and molecular docking. Retrospective validation was performed using a database of non-active compounds, and early enrichment of EBOV actives at different false positive rates was calculated.
    [Show full text]
  • Viribus Unitis: Drug Combinations As a Treatment Against COVID-19
    Viribus Unitis: Drug Combinations as a Treatment against COVID-19 Eugene N. Muratova,* and Alexey Zakharovb a Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA. b National Center for Advancing Translational Sciences (NCATS), 9800 Medical Center Drive, Rockville, Mar land 20850, United States Corresponding Authors * Address for correspondence: 301 Beard Hall, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA; Telephone: (919) 966-3459; FAX: (919) 966- 0204; E-mail: [email protected] Abstract The opportunities that may be provided by synergistic antiviral action of drugs for battling SARS-CoV2 are currently underestimated. Modern AI technologies realized as text, data, and knowledge mining and analytics tools provide the researchers with unprecedented opportunities for “smart” design of drug combinations with synergistic antiviral activities. The goal of this study is to emphasize the combination therapy as a potential treatment against COVID-19 and to utilize the combination of modern machine learning and AI technologies with our expertise to select the most promising drug combinations with further experimental validation. To the best of our knowledge, we are the first who applied the combination of data, text, and knowledge mining and modeling towards identification of drug combinations against SARS-CoV2. As a result, we have identified 281 combinations of 38 drugs that may serve as potential treatment for COVID-19. Among them, we selected twenty binary combinations that were submitted to experimental testing and twenty treble drug combinations that will be submitted for experimental testing as soon as necessary infrastructure will be developed.
    [Show full text]
  • Current Evidence for COVID-19 Therapies: a Systematic
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.18.20248452; this version posted December 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Treatment and prevention SLR Current evidence for COVID-19 therapies: a systematic literature review Tobias Welte1, Lucy J. Ambrose2, Gillian C. Sibbring3, Shehla Sheikh4, Hana Müllerová4, Ian Sabir4 1Department of Pulmonary and Infectious Diseases, Hannover University School of Medicine, Germany. 2Prime Global, Oxford, UK. 3Prime Global, Knutsford, UK; 4AstraZeneca, Cambridge, UK. Corresponding author: Tobias Welte, Department of Pulmonary and Infectious Diseases, Hannover University School of Medicine, Welfengarten 1, 30167 Hannover, Germany Tel: +495115323531 Email address: [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Page 1 medRxiv preprint doi: https://doi.org/10.1101/2020.12.18.20248452; this version posted December 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Treatment and prevention SLR Abstract Effective therapeutic interventions for the treatment and prevention of COVID-19 are urgently needed. A systematic review was conducted to identify clinical trials of pharmacological interventions for COVID-19 published between 1 December 2019 and 14 October 2020. Data regarding efficacy of interventions, in terms of mortality, hospitalisation and need for ventilation, were extracted from identified studies and synthesised qualitatively.
    [Show full text]
  • ESCMID Online Lecture Library © by Author
    Albert Osterhaus Head Dept Virology Chairman ESWI CSO Viroclinics-Biosciences BV Library Pandemic flu and the anti-H1N1 vaccine: Lecture a retrospective view. author Onlineby © ESCMID ESCMID conference on the impact of vaccines on Public Health Prague, 2nd April 2011 Human influenza: three appearances Library Seasonal influenza (A: H3N2, H1N1; B) Lecture Avian influenza author (A: H7N7, H5N1…)Online by © PandemicESCMID influenza (A: H1N1, H2N2, H3N2, H1N1…?) INFLUENZA A VIRUS Recent zoonotic transmissions Library Subtype Country Year # Cases # Deaths H7N7 UK Lecture1996 1 0 H5N1 Hongkong 1997 18 6 H9N2 SE-Asia 1999author >2 0 H5N1 HongkongOnlineby 2003 2? 1 H7N7 Netherlands© 2003 89 1 H7N2 USA 2003 1 0 H7N3 Canada 2004 2 0 H5N1ESCMIDSE-Asia/M-East/ 2003-11 .>500 >300* Europe/W-Africa *CFR ~ 60% Library Lecture author Onlineby © ESCMID Confirmed H5N1 avian influenza virus endemic areas (poultry and wild birds) since 2003 Avian influenza A H5N1 virus - HA: Receptor specificity - Library Shinya et al., Nature 440, 2006 Lecture Van Riel et al., Science 2006 author Van Riel et al., Online Am J Pathol 2007 by Van Riel et al., © Am J Pathol 2009 Van Riel et al., ESCMID Am J Pathol 2010 Library Lecture author Onlineby © ESCMID Introduction - Attachment to the upper respiratory tract - Seasonal H3N2 Pandemic H1N1 HPAIV H5N1 Last four pandemics Library Lecture Credit: US National Museum of Health and Medicine author 1918 1957Online 1968 2009 “Spanish Flu” “Asian Flu” by “Hong Kong Flu” © ”Swine Flu” >40 million deaths 1-4 million deaths 1-4million deaths ??? A(H1N1)ESCMIDA(H2N2) A(H3N2) A(H1N1) Library Lecture author Onlineby © ESCMID Air traffic from Mexico ~ 1998 PB2,PA: Triple reassortant ~ 1968 ~ 1998 PB1: LibraryN-America ~ 1918 Classical swine HA, NP, NS: Lecture ~ 1979 NA, MA: authorEurasian swine Eurasia Onlineby A/California/4/2009 © PB2 PB1 The H1N1v flu virus PA Courtesy: Ron Fouchier HA NP ESCMID NA MA NS Library Lecture author Onlineby © ESCMID The Mexican flu virus..
    [Show full text]
  • Pre-Existing Immunity Provides a Barrier to Airborne Transmission of Influenza Viruses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.15.103747; this version posted June 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Pre-existing immunity provides a barrier to airborne transmission of influenza viruses Valerie Le Sage1, Jennifer E. Jones1, Karen A. Kormuth1^, William J. Fitzsimmons2, Eric Nturibi1, Gabriella H. Padovani1, Claudia P. Arevalo4, Andrea J. French1, Annika J. Avery1, Richard Manivanh1, Elizabeth E. McGrady1, Amar R. Bhagwat1^, Adam S. Lauring2,3, Scott E. Hensley4, Seema S. Lakdawala1,5* 1 - Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 2 – Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 3 – Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 4 – Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 5 - Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219 * Send all correspondence to [email protected] ^ Current position - KAK is an Assistant Professor at Bethany College, Bethany, WV and ARB is a Senior Project Engineer at II-VI Aerospace & Defense in Dayton, OH. Abstract Human-to-human transmission of influenza viruses is a serious public health threat, yet the precise role of immunity from previous infections on the susceptibility to airborne viruses is still unknown. Using human seasonal influenza viruses in a ferret model, we examined the roles of exposure duration and heterosubtypic immunity on influenza transmission. We found that airborne transmission of seasonal influenza strains is abrogated in recipient animals with pre-existing non- neutralizing immunity, indicating that transmissibility of a given influenza virus strain should be examined in the context of ferrets that are not immunologically naïve.
    [Show full text]
  • Drugs in COVID‐19 Clinical Trials: Predicting Transporter‐Mediated
    UCSF UC San Francisco Previously Published Works Title Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data. Permalink https://escholarship.org/uc/item/77434779 Journal Clinical pharmacology and therapeutics, 110(1) ISSN 0009-9236 Authors Yee, Sook Wah Vora, Bianca Oskotsky, Tomiko et al. Publication Date 2021-07-01 DOI 10.1002/cpt.2236 Peer reviewed eScholarship.org Powered by the California Digital Library University of California ARTICLE Drugs in COVID- 19 Clinical Trials: Predicting Transporter- Mediated Drug- Drug Interactions Using In Vitro Assays and Real- World Data Sook Wah Yee1,†, Bianca Vora1,†, Tomiko Oskotsky2, Ling Zou1, Sebastian Jakobsen1, Osatohanmwen J. Enogieru1, Megan L. Koleske1, Idit Kosti2, Mattias Rödin1, Marina Sirota2 and Kathleen M. Giacomini1,* Numerous drugs are currently under accelerated clinical investigation for the treatment of coronavirus disease 2019 (COVID- 19); however, well- established safety and efficacy data for these drugs are limited. The goal of this study was to predict the potential of 25 small molecule drugs in clinical trials for COVID- 19 to cause clinically relevant drug- drug interactions (DDIs), which could lead to potential adverse drug reactions (ADRs) with the use of concomitant medications. We focused on 11 transporters, which are targets for DDIs. In vitro potency studies in membrane vesicles or HEK293 cells expressing the transporters coupled with DDI risk assessment methods revealed that 20 of the 25 drugs met the criteria from regulatory authorities to trigger consideration of a DDI clinical trial. Analyses of real- world data from electronic health records, including a database representing nearly 120,000 patients with COVID- 19, were consistent with several of the drugs causing transporter- mediated DDIs (e.g., sildenafil, chloroquine, and hydroxychloroquine).
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof Ongoing Clinical Trials for the Management of the COVID-19 Pandemic M.P. Lythgoe, P. Middleton PII: S0165-6147(20)30070-5 DOI: https://doi.org/10.1016/j.tips.2020.03.006 Reference: TIPS 1706 To appear in: Trends in Pharmacological Sciences Please cite this article as: M.P. Lythgoe and P. Middleton, Ongoing Clinical Trials for the Management of the COVID-19 Pandemic, Trends in Pharmacological Sciences (2020), https://doi.org/10.1016/j.tips.2020.03.006 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier. Journal Pre-proof Ongoing Clinical Trials for the Management of the COVID-19 Pandemic *MP Lythgoe1 & *P Middleton2 1Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, W120HS, London, UK 2 Department of Metabolism, Digestion & Reproduction, Imperial College London, St Marys Hospital, Praed Street, W21NY, London UK *Equal contribution Corresponding Email: [email protected] Key words: Coronavirus, SARS-CoV-2, COVID-19, 2019-nCoV, pandemic ABSTRACT COVID-19 has rapidly developed into a worldwide pandemic causing a significant health and economic burden.
    [Show full text]
  • B Cell Responses Against Influenza Viruses
    viruses Review B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat Jenna J. Guthmiller 1,* , Henry A. Utset 1 and Patrick C. Wilson 1,2 1 Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA; [email protected] (H.A.U.); [email protected] (P.C.W.) 2 Committee on Immunology, University of Chicago, Chicago, IL 60637, USA * Correspondence: [email protected] Abstract: Antibodies are critical for providing protection against influenza virus infections. However, protective humoral immunity against influenza viruses is limited by the antigenic drift and shift of the major surface glycoproteins, hemagglutinin and neuraminidase. Importantly, people are exposed to influenza viruses throughout their life and tend to reuse memory B cells from prior exposure to generate antibodies against new variants. Despite this, people tend to recall memory B cells against constantly evolving variable epitopes or non-protective antigens, as opposed to recalling them against broadly neutralizing epitopes of hemagglutinin. In this review, we discuss the factors that impact the generation and recall of memory B cells against distinct viral antigens, as well as the immunological limitations preventing broadly neutralizing antibody responses. Lastly, we discuss how next-generation vaccine platforms can potentially overcome these obstacles to generate robust and long-lived protection against influenza A viruses. Keywords: influenza viruses; humoral immunity; broadly neutralizing antibodies; imprinting; Citation: Guthmiller, J.J.; Utset, H.A.; hemagglutinin; germinal center; plasma cells Wilson, P.C. B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat. Viruses 2021, 13, 1.
    [Show full text]
  • Cellular Responses to 2009 Pandemic H1n1 Influenza in A
    Characterisation of Cellular Responses to Pandemic Influenza in Naturally Infected Individuals Shaima Begom Imperial College London National Heart and Lung Institute Submitted for the degree of PhD February 2015 I DECLARATION OF ORIGINALITY I certify that this thesis, and the research to which it refers, are the product of my own work, conducted during the years 2010 and 2014 of the PhD in the Section of Respiratory Medicine at Imperial College London. Any ideas or quotations from the work of other people published or otherwise, or from my own previous work are fully acknowledged in accordance with the standard referencing practices of the discipline. Furthermore, I would like to acknowledge Professor Ajit Lalvani and Dr Saranya Sridhar who designed the ImmunoFlu study cohort. Dr Sridhar recruited subjects for the ImmunoFlu study, and I participated in collection and bio-banking of biological samples during the PhD period. Dr Sridhar and I equally contributed to the laboratory work presented in Results sections 3.2 and 3.3 of this thesis. II COPYRIGHT DECLARATION “The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the licence terms of this work.” Registry, Imperial College London. “Since 2003, ownership of copyright in original research articles remains with the Authors*, and provided that, when reproducing the Contribution or extracts from it, the Authors acknowledge first and reference publication in the Journal, the Authors retain the following non-exclusive rights: a.
    [Show full text]
  • The Compelling Need for Game-Changing Influenza Vaccines
    THE COMPELLING NEED FOR GAME-CHANGING INFLUENZA VACCINES AN ANALYSIS OF THE INFLUENZA VACCINE ENTERPRISE AND RECOMMENDATIONS FOR THE FUTURE OCTOBER 2012 The Compelling Need for Game-Changing Influenza Vaccines An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future Michael T. Osterholm, PhD, MPH Nicholas S. Kelley, PhD Jill M. Manske, PhD, MPH Katie S. Ballering, PhD Tabitha R. Leighton, MPH Kristine A. Moore, MD, MPH The Center for Infectious Disease Research and Policy (CIDRAP), founded in 2001, is a global leader in addressing public health preparedness and emerging infectious disease response. Part of the Academic Health Center at the University of Minnesota, CIDRAP works to prevent illness and death from targeted infectious disease threats through research and the translation of scientific information into real-world, practical applications, policies, and solutions. For more information, visit: www.cidrap.umn.edu. This report was made possible in part by a grant from the Alfred P. Sloan Foundation. This report is available at: www.cidrap.umn.edu This report was produced and designed by Betsy Seeler Design. © 2012 Regents of the University of Minnesota. All rights reserved. Contents Preface...............................................................................................................................................................2 Executive Summary..........................................................................................................................................5 Chapter.1.
    [Show full text]
  • (COVID-19) Through Virtual Screening Targeting SARS-Cov-2 Main Protease
    biology Article Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease Kamrul Hasan Chowdhury 1,†, Md. Riad Chowdhury 1,†, Shafi Mahmud 2, Abu Montakim Tareq 1 , Nujhat Binte Hanif 1, Naureen Banu 1, A. S. M. Ali Reza 1,* , Talha Bin Emran 3,* and Jesus Simal-Gandara 4,* 1 Department of Pharmacy, International Islamic University Chittagong, Chittagong 4318, Bangladesh; [email protected] (K.H.C.); [email protected] (M.R.C.); [email protected] (A.M.T.); [email protected] (N.B.H.); [email protected] (N.B.) 2 Microbiology Laboratory, Bioinformatics Division, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi 6205, Bangladesh; shafi[email protected] 3 Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh 4 Nutrition and Bromatology Group, Department of Analytical and Food Chemistry, Faculty of Food Science and Technology, University of Vigo–Ourense Campus, E32004 Ourense, Spain * Correspondence: [email protected] (A.S.M.A.R.); [email protected] (T.B.E.); [email protected] (J.S.-G.) † These authors contributed equally to this work. Simple Summary: With the urgent necessity of potential treatment against novel coronavirus disease, we used several computational methods to search for active drugs from an extensive database. The results of our investigation suggested several established drugs that can be subjected to further analysis for the treatment of novel coronavirus disease. Various methods used in this study proved the effectiveness of the retrieved drugs. Therefore, our findings highly recommend the mentioned drugs to be scrutinized to discover drugs against novel coronavirus.
    [Show full text]